Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Short-Term Debt repayments (2020 - 2025)

Ani Pharmaceuticals' Short-Term Debt repayments history spans 6 years, with the latest figure at -$6.1 million for Q4 2025.

  • On a quarterly basis, Short-Term Debt repayments fell 102.09% to -$6.1 million in Q4 2025 year-over-year; TTM through Sep 2025 was $297.1 million, a 39712.4% increase, with the full-year FY2024 number at $292.5 million, changed N/A from a year prior.
  • Short-Term Debt repayments hit -$6.1 million in Q4 2025 for Ani Pharmaceuticals, down from $2.0 million in the prior quarter.
  • Over the last five years, Short-Term Debt repayments for ANIP hit a ceiling of $291.0 million in Q4 2024 and a floor of -$6.1 million in Q4 2025.
  • Historically, Short-Term Debt repayments has averaged $30.6 million across 5 years, with a median of $1.4 million in 2022.
  • Biggest five-year swings in Short-Term Debt repayments: soared 13033.33% in 2024 and later plummeted 102.09% in 2025.
  • Tracing ANIP's Short-Term Debt repayments over 5 years: stood at $192.1 million in 2021, then crashed by 101.17% to -$2.2 million in 2022, then changed by 0.0% to -$2.2 million in 2023, then soared by 13033.33% to $291.0 million in 2024, then plummeted by 102.09% to -$6.1 million in 2025.
  • Business Quant data shows Short-Term Debt repayments for ANIP at -$6.1 million in Q4 2025, $2.0 million in Q3 2025, and $2.0 million in Q2 2025.